Edition:
United States

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

34.79USD
11:44am EST
Change (% chg)

$0.19 (+0.55%)
Prev Close
$34.60
Open
$34.50
Day's High
$35.07
Day's Low
$34.48
Volume
710,310
Avg. Vol
1,612,022
52-wk High
$47.81
52-wk Low
$30.34

Select another date:

Mon, Nov 19 2018

EU cracks down on blood pressure medicine made by Mylan

European Union authorities on Monday stepped in to effectively ban sales of blood pressure medicine valsartan made by an India-based unit of Mylan NV after some batches were found to contain a probable cancer-causing impurity, the latest in a global crackdown.

UPDATE 1-EU cracks down on blood pressure medicine made by Mylan

Nov 19 European Union authorities on Monday stepped in to effectively ban sales of blood pressure medicine valsartan made by an India-based unit of Mylan NV after some batches were found to contain a probable cancer-causing impurity, the latest in a global crackdown.

European authorities crack down on blood pressure medicine made by Mylan

Nov 19 European Union authorities are cracking down on blood pressure medicine valsartan made by a unit of Mylan NV after an impurity was found in some batches of the treatment.

Mylan and Theravance's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

UPDATE 2-Mylan and Theravance's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Mylan and Theravance Biopharma's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Drugmaker Mylan's profit beats; puts no timeline on strategic options

Mylan NV beat analysts' estimates for third-quarter profit on Monday, as the generic drugmaker reported higher sales of its products in emerging markets and said it had not set any timeline on evaluating its strategic alternatives.

UPDATE 3-Drugmaker Mylan's profit beats; puts no timeline on strategic options

Nov 5 Mylan NV beat analysts' estimates for third-quarter profit on Monday, as the generic drugmaker reported higher sales of its products in emerging markets and said it had not set any timeline on evaluating its strategic alternatives.

Mylan's quarterly revenue falls 4 pct

Nov 5 Drugmaker Mylan NV reported a 4 percent fall in third-quarter revenue on Monday, hit by low prices of generic drugs in the United States and a continuing global shortage of its emergency allergy injection EpiPen.

Plaintiffs seek sanctions against Mylan in EpiPen litigation

Lawyers for consumers who accuse Mylan NV of engaging in an unlawful scheme to squelch competition for its EpiPen allergy treatment have asked a federal judge to sanction the drugmaker for interfering with subpoenas they issued to its vendors.

Select another date: